Related Experiment Videos
Steady-state valproate pharmacokinetics during long term therapy.
Clinical and Experimental Neurology
|January 1, 1983
Summary
Long-term valproate therapy in epileptic patients shows stable pharmacokinetics. Drug disposition in the body remains consistent, unlike some other anticonvulsants.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Neuroscience
Background:
- Valproate is a widely used anticonvulsant medication.
- Understanding long-term drug disposition is crucial for effective epilepsy management.
- Comparative bioavailability studies inform therapeutic strategies.
Purpose of the Study:
- To investigate the steady-state pharmacokinetics of valproate in epileptic patients undergoing long-term therapy.
- To compare the disposition of valproate (sodium salt and free acid) after prolonged use.
- To assess if long-term valproate therapy alters drug metabolism and elimination.
Main Methods:
- Study involved 8 epileptic patients with established long-term valproate treatment.
- Pharmacokinetic parameters including elimination half-life, volume of distribution, and plasma clearance were measured.
- Valproate administered as both sodium salt and free acid forms were analyzed.
Main Results:
- Mean elimination half-life: 8.21 ± 3.13 hours.
- Mean apparent volume of distribution: 0.1868 ± 0.0641 L/kg.
- Mean plasma clearance: 0.0177 ± 0.0099 L/kg/hour.
- These pharmacokinetic parameters were comparable to those reported in single-dose studies.
Conclusions:
- Long-term valproate therapy does not significantly alter the drug's disposition in the human body.
- Unlike certain other anticonvulsants (e.g., carbamazepine), valproate's pharmacokinetic profile remains stable over time.
- This stability supports consistent therapeutic efficacy and predictable dosing in chronic epilepsy management.